Looking To Compete With BioMarin, Ascendis Continues Its Growth Story

robot
Abstract generation in progress

Ascendis Pharma A/S experienced significant sales growth in 2025 and anticipates a new product approval in 2026. This growth positions Ascendis to compete more directly with BioMarin Pharmaceutical Inc. The article suggests that Ascendis is continuing its positive trajectory in the market.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
0/400
No comments
  • Pin

Trade Crypto Anywhere Anytime
qrCode
Scan to download Gate App
Community
English
  • 简体中文
  • English
  • Tiếng Việt
  • 繁體中文
  • Español
  • Русский
  • Français (Afrique)
  • Português (Portugal)
  • Bahasa Indonesia
  • 日本語
  • بالعربية
  • Українська
  • Português (Brasil)